Author of

• 10801

  +

  P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10807

    +

    P1.11-006 - Tyrosine kinase inhibitors versus chemotherapy in patients with metastatic Non-Small Cell Lung Cancer harboring EGFR mutation: Venezuelan experience (ID 699)

    09:30 - 09:30  |  Author(s): M.B. Fuentes
    • Abstract

    Background
    Lung cancer is the first cause of death globally. Platinum based chemotherapy is the standard of care for NSCLC. Maintenance therapy and switch therapy with novel agents have shown clinical benefit. The determination of the mutation of EGFR, allowed personalized therapy with tyrosine kinase inhibitors, providing benefit in terms of progression free survival and quality of life to those patient harboring the mutation.

    Methods
    An observational, analytic and descriptive study was conducted in Venezuela. 36 patients harboring the EGFR mutation were submitted to chemotherapy or tyrosine kinase inhibitors. The primary endpoint was the determination of the clinical benefit in terms of progression free survival according to the first line therapy.

    Results
    From a total of 296 patients with lung adenocarcinoma, the mutation rate was 12.2%. The EGFR mutation was found more frequently in patients with adenocarcinoma histology, males, less than 65 years old and those who were former smokers or nonsmokers. The most common type of mutation of the EGFR was found in the EXON 21, followed by EXON 19. 31 of these patients received first-line treatment with chemotherapy and 5 with tyrosine kinase inhibitors. The median progression-free survival for patients receiving tyrosine kinase inhibitors was 10 months and for those who received chemotherapy was 6 months. These findings were statistically significant (p = 0.03). Regarding the overall survival, no statistical significance was found, probably due to the crossing-over of the treatment.

    Conclusion
    The clinical benefit evidenced in Venezuelan patients harboring the EGFR mutation when treated with tyrosine kinase inhibitors in first and second line, was superior to the one shown by patients who received chemotherapy. These results are similar to those evidenced in clinical trials done worldwide. On this basis, we concluded that tyrosine kinase inhibitors should be used as first-line treatment in patients with EGFR mutation or during the course of their disease.